Pacific Biosciences, formerly known as Nanofluidics, a Menlo Park, Calif. company focused on medications resulting from DNA gene sequencing, has raised around $50 million in a forth round of funding.

Investors include Maverick Capital, and return backers Alloy Ventures, Kleiner Perkins Caufield & Byers and Mohr, Davidow Ventures, according to PE Week, which first reported the funding today. Pacific Biosciences previously has raised more than $15M.

Here is an article about its technology (free after registration).

(This story first posted 1/12)